Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1401 - 1450 of 1864 results
- VB4-845: A conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer.
- Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects.
- Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With Cyclophosphamide.
- Intralesional Adenovirus-mediated Interleukin-2 Gene Transfer for Advanced Solid Cancers and Melanoma.
- Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer.
- Nanoparticles target distinct dendritic cell populations according to their size.
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer.
- A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer.
- Surmounting Tumor-induced Immune Suppression by Frequent Vaccination or Immunization in the Absence of B Cells.
- Small Cleavable Adapters Enhance the Specific Cytotoxicity of a Humanized Immunotoxin Directed Against CD64-positive Cells.
- Utility of a herpes oncolytic virus for the detection of neural invasion by cancer.
- Immunomodulatory drugs Revlimid((R)) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
- Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
- Photodynamic therapy with recombinant adenovirus AdmIL-12 enhances anti-tumour therapy efficacy in human papillomavirus 16 (E6/E7) infected tumour model.
- Novel Cancer Antiangiotherapy Using the VEGF Promoter-targeted Artificial Zinc-finger Protein and Oncolytic Adenovirus.
- Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.
- Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.
- Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
- Cluster intradermal DNA vaccination rapidly induces E7-specific CD8(+) T-cell immune responses leading to therapeutic antitumor effects.
- First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma.
- Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
- Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.
- Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses.
- Interleukin 21 enhances antibody-mediated tumor rejection.
- Disrupted Expression of CXCL5 in Colorectal Cancer Is Associated with Rapid Tumor Formation in Rats and Poor Prognosis in Patients.
- Treatment of Cancer with a Novel Dual-Targeted Conditionally Replicative Adenovirus Armed with mda-7/IL-24 Gene.
- Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
- Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo.
- Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
- Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.
- Vascular normalization in Rgs5-deficient tumours promotes immune destruction.
- Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
- Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors.
- Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
- Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model.
- Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis.
- Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study.
- The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: A retrospective analysis of enrolled cases in Japan.
- Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases.
- Establishment of CXCR4-small interfering RNA retrovirus vector driven by human prostate-specific antigen promoter and its biological effects on prostate cancer in vitro and in vivo.
- Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells.
- A Critical Role of CCR7 in Invasiveness and metastasis of SW620 Colon Cancer Cell in Vitro and in Vivo.
- Monitoring Circulating Tumor Cells in Cancer Vaccine Trials.
- Anti-erbb4 targeted therapy combined with radiation therapy in prostate cancer: Results of in-vitro and in-vivo studies.
- Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells.
- Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
- Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.
- Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation.
- Trastuzumab plus Paclitaxel or Docetaxel in HER-2-Negative/HER-2 ECD-Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer.
- Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer.